November 8, 2021

The Honorable Patrick Leahy
Chairman
U.S. Senate Committee on Appropriations
Washington, DC 20515

The Honorable Rosa DeLauro
Chairwoman
U.S. House Committee on Appropriations
Washington, DC 20510

The Honorable Richard Shelby
Ranking Member
U.S. Senate Committee on Appropriations
Washington, DC 20515

The Honorable Kay Granger
Ranking Member
U.S. House Committee on Appropriations
Washington, DC 20510

Re: Support for House-Passed Appropriations for Newborn Screening Programs

Dear Majority Leader Schumer, Speaker Pelosi, and Minority Leaders McConnell and McCarthy;

Thank you for your leadership on the Fiscal Year (FY) 2022 Labor, Health and Human Services, Education, and Related Agencies (LHHS) Appropriations legislation. The undersigned organizations, committed to the health of our nation’s mothers, infants, children, and families, want to sincerely express our gratitude for the funding included in H.R. 4502 for programs that provide critical support to state newborn screening (NBS) programs. As negotiations on appropriations for FY 2022 continue, we urge that the funding included in H.R. 4502 for state newborn screening programs be maintained in the final appropriations bill negotiated by the House of Representatives and Senate.

H.R. 4502 appropriates $23 million to the Centers for Disease Control and Prevention’s (CDC) Environmental Health Laboratory to support its newborn screening activities, approximately $26 million to the Health Resources and Services Administration’s (HRSA) Heritable Disorders program, and adequate funding for the National Institutes of Health (NIH) Child Health and Human Development program. These levels represent a $5 million increase in funding for CDC’s newborn screening efforts and $7 million increase for HRSA’s newborn screening programs.

For almost 60 years, newborn screening has been saving and improving the lives of children across the United States through early identification of diseases, which, if not identified and treated early, can cause permanent disability or death. It is unquestionably one of the most successful public health programs of our time, positively impacting millions of children and their families, and the researchers who use those blood spots in order to further understand and refine the tests for those diseases. For example, the CDC has demonstrated the impact of newborn screening for critical congenital heart disease, finding that infant deaths from CCHD decreased more than 33% in states with mandatory screening compared to states with no mandatory screening policies. Additionally, deaths from other or unspecified cardiac causes decreased by 21% due to the NBS program.¹

The CDC, HRSA, and NIH each play a crucial role in supporting state newborn screening programs. The CDC’s Environmental Health Laboratory performs quality testing for more than 500 laboratories to ensure the accuracy of newborn screening tests in the United States and around the world. Further, the CDC helps states implement new screening tests and works with partners to develop new screening tests for specific disorders.

HRSA’s Heritable Disorders Program provides assistance to states to improve and expand their newborn screening programs and to promote parent and provider education. HRSA also supports the work of the Advisory Committee on Heritable Disorders in Newborns and Children, which provides states with a Recommended Uniform Screening Panel (RUSP) to help ensure every infant is screened for 35 conditions that have a recognized treatment. We hope that the funding included in H.R. 4502 will allow continued research and development on the RUSP, which has not added any new conditions since 2018.2

The NIH’s National Institute of Child Health and Human Development (NICHD) conducts research to improve technical aspects of newborn screening tests in order to advance their sophistication and utility. The NICHD research aims to identify, develop, and test the most promising newborn screening technologies, increase the specificity of newborn screening, expand the number of conditions for which screening tests are available, and improve and evaluate treatments and disease management strategies for detectable conditions that can currently be treated and for other genetic metabolic, hormonal, and/or functional conditions that can be detected through newborn screening for which treatment is not yet available.3

In 2007, prior to the passage of the Newborn Screening Saves Lives Act, only 10 states and the District of Columbia required infants to be screened for all 29 disorders that were recommended at that time. Today, all 50 states, the District of Columbia, and Puerto Rico require screening for at least 31 of the 35 core conditions on the RUSP.4

We deeply appreciate your efforts to date to increase support for these vital public health programs in FY2022. The modest federal investment in state newborn screening programs yields outstanding dividends in health outcomes and infants’ and families’ quality of life. We thank you for your attention and look forward to working with you to ensure that the United States identifies and treats each of the 1 in 300 infants who has a condition that can be detected through newborn screening. If you have questions, please do not hesitate to reach out to Paul Melmeyer at the Muscular Dystrophy Association at pmelmeyer@mdausa.org, or Jay Nichols at the March of Dimes at jnichols@marchofdimes.org.

Sincerely,

ALD Alliance
American Academy of Pediatrics
American Association for Clinical Chemistry
American College of Medical Genetics and Genomics
Association of Maternal & Child Health Programs
Association of Public Health Laboratories
Cure SMA
EveryLife Foundation for Rare Diseases
The Firefly Fund
HCU Network America
Hunter’s Hope Foundation
Immune Deficiency Foundation
March of Dimes
Muscular Dystrophy Association
National Organization for Rare Disorders
Rare Disease Innovations Institute, Inc.
Save Babies Through Screening Foundation
Society for Inherited Metabolic Disorders